A leadless pacing device may include a housing having a proximal end and a distal end, and one or more electrodes supported by the housing. The housing may include a body portion and a header. A distal extension may extend distally from the header of the housing, the distal extension including one or more electrodes. The header may include a guide wire port and a guide wire lumen may extend from the guide wire port through the header of the housing and through the distal extension. A fixation member may extend from the header of the housing. The header may be formed from an over mold process.

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate and a hemostatic agent. The substrate includes a first piece and a second piece that is joined with the first piece. The first piece includes the hemostatic agent and the second piece includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

This document describes methods and devices for securing epicardial devices. For example, this document describes methods and devices for securing epicardial devices by passing a sheath into a pericardial space of a patient through a first percutaneous access site, passing a guidewire through the sheath into the pericardial space of the patient, passing the guidewire through a transverse sinus of the patient, passing a snare device into the pericardial space through a second percutaneous access site, and capturing a free end portion of the guidewire using the snare device.

A biostimulator, such as a leadless cardiac pacemaker, including an electrical feedthrough assembly mounted on a housing, is described. An electronics compartment of the housing can contain an electronics assembly to generate a pacing impulse, and the electrical feedthrough assembly can include an electrode tip to deliver the pacing impulse to a target tissue. A monolithically formed electrode body can have a pin integrated with a cup. The pin can be electrically connected to the electronics assembly, and the cup can be electrically connected to the electrode tip. Accordingly, the biostimulator can transmit the pacing impulse through the monolithic pin and cup to the target tissue. The cup can hold a filler having a therapeutic agent for delivery to the target tissue and may include retention elements for maintaining the filler at a predetermined location within the cup.

Disclosed herein is an implantable medical device for implantation against cardiac tissue in the administration of electrotherapy to the cardiac tissue. The device includes a distal end and a monolithic controlled release device. The distal end includes a housing structure and a cavity within the housing structure. The cavity opens exterior the implantable medical device via a distal opening. The monolithic controlled release device is within the cavity and proximal the distal opening. The monolithic controlled release device includes a distal face, a proximal face opposite the distal face, an outer circumferential surface extending between the distal face and the proximal face, and a spline-shaped inner lumen extending between the distal face and the proximal face and radially inward from the outer circumferential surface. The monolithic controlled release device further includes an active pharmaceutical ingredient.

A distal electrode of an electrode assembly, for example, employed by an implantable medical electrical lead device, extends distally from a distal terminal end of a sleeve of the assembly; and the sleeve, which defines a longitudinal axis of the assembly, includes a plurality of channels that provide fluid communication between a steroid eluting component, which is seated in an external groove of the sleeve, and an area distal to the distal terminal end of the sleeve. Floors of some or all of the sleeve channels may angle toward the longitudinal axis of the assembly, being closer to the axis at the distal terminal end of the sleeve. The assembly may further include a proximal electrode secured to a proximal end of the sleeve, wherein the proximal electrode may be mounted around an outer surface of the sleeve or coupled to the sleeve by means of a coupling component.

An implantable medical lead having an elongated lead body extending from a proximal end to a distal end, at least one conductor extending within the lead body from the proximal end to the distal end, and a fixation member having a proximal end and a distal end, the proximal end of the electrode configured to be electrically coupled to the distal end of the lead body. The fixation member includes a first delivery port and a second delivery port for releasing a therapeutic agent from the fixation member to tissue of a patient, wherein the first delivery port is positioned along the proximal end of the fixation member to deliver the therapeutic agent to endothelial cells along an endothelial layer of tissue, and the second delivery port is positioned along the distal end of the fixation member and spaced a distance from the first delivery port to deliver the therapeutic agent to myocardial tissue within a myocardial layer of the tissue, and wherein no delivery ports are positioned within the distance that the second delivery port is spaced from the first delivery port.

An electrode head of an implantable electrode line, the electrode head including an elongate housing which has a longitudinal axis. The elongate housing includes at least two housing parts, which are cylinder-segment-shaped at least in portions and are fixedly joined together to form the electrode head along the longitudinal axis.

The present invention relates to an implantable cardiac device. The implantable cardiac device comprises a planar spiral for attaching the implantable cardiac device to a patient's tissue.

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate and a hemostatic agent. The substrate includes a first piece and a second piece that is joined with the first piece. The first piece includes the hemostatic agent and the second piece includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.